This site is intended for healthcare professionals

TAVO + Keytruda demonstrated 41% overall response rate and 36% complete response in a late-stage metastatic melanoma study featured in 'Clinical Cancer Research'.- Oncosec Medical.

Read time: 1 mins
Last updated:16th Mar 2021
Published:8th May 2020
Condition: Metastatic Melanoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest